Nakagawa-Goto, K.Nakamura, S.Bastow, K.F.Nyarko, A. K.Peng, C.Y.Lee, F.Y.Lee, K.H.2012-05-032017-10-162012-05-032017-10-162007http://197.255.68.203/handle/123456789/1035Sixteen different taxoid conjugates were prepared by linking various anticancer compounds, including camptothecin (CPT), epipodophyllotoxin (EP), colchicine (COL), and glycyrrhetinic acid (GA), at the 20- or 7-position on paclitaxel (TXL, 1) through an ester, imine, amine, or amide bond. Newly synthesized conjugates were evaluated for cytotoxic activity against replication of several human tumor cell lines. Among them, TXL–CPT conjugates, 8–10, were more potent than TXL itself against the human prostate carcinoma cell line PC-3 (ED50 = 14.8, 3.1, 19.4 nM compared with 55.5 nM), and conjugate 10 was also 8-fold more active than TXL against the LN-CAP prostate cancer cell line. These compounds also possessed anti-angiogenesis ability as well as lower inhibitory effects against a normal cell line (MRC-5). Thus, conjugates 8–10 are possible antitumor drug candidates, particularly for prostate cancer.enPaclitaxelConjugationCytotoxicityProstate cancerArticle